Q-omics provides the consensus-scored PTGFR profile across patient tissues and cancer cell-line models. PTGFR expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTGFR is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, PTGFR RNA expression shows 20,383 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where PTGFR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTGFR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTGFR survival associations across molecular data types. PTGFR RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTGFR RNA expression–survival associations across cancer types. High PTGFR expression shows unfavorable associations in KIRP, MESO and STAD, but favorable associations in HNSC, ACC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTGFR RNA expression.
This table summarizes PTGFR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PTGFR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTGFR shows lower tumor expression in BLCA, KIRC, KICH, LUAD, THCA and LUSC. The BLCA box plot shows higher PTGFR RNA expression in normal versus tumor tissue (log2 FC = −3.482, t-test p < 0.001).
This table shows molecular features associated with PTGFR in patient tissues and cancer cell lines. In patient samples, PTGFR shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTGFR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
